<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:linked-data-default="http://data-service.theglobalfund.org/api" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <iati-identifier>47045-UZB-T-RSSPMCPhP</iati-identifier>
  <reporting-org ref="47045" secondary-reporter="0" type="30">
   <narrative xml:lang="EN">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Reduce Tuberculosis incidence and mortality in the Republic of Uzbekistan</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Uzbekistan - Tuberculosis.  This program has the following goals: To improve TB diagnosis, treatment and care while strengthening TB control service, shifting to outpatient care, optimizing hospital infrastructure, developing human resources and improving infection control.. The objectives of this program are: To increase detection of TB and DR TB by providing access for all TB patients to quality assured laboratory diagnostics.  To improve quality of TB and DR TB treatment in adults and children by securing an uninterrupted supply of quality assured anti TB drugs and necessary quality assured treatment monitoring</narrative>
  </description>
  <participating-org role="3" type="15">
   <narrative xml:lang="EN">CCM Uzbekistan</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">CCM Uzbekistan</narrative>
  </participating-org>
  <participating-org ref="47045" role="1" type="30">
   <narrative xml:lang="EN">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
  </participating-org>
  <other-identifier ref="966f2c63-42f9-4152-8faf-0613b4a63663" type="A1">
   <owner-org ref="47045">
    <narrative xml:lang="EN">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
   </owner-org>
  </other-identifier>
  <other-identifier ref="UZB-T-RSSPMCPhP" type="A1">
   <owner-org ref="47045">
    <narrative xml:lang="EN">The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
   </owner-org>
  </other-identifier>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2020-11-04" type="1"></activity-date>
  <activity-date iso-date="2020-11-04" type="2"></activity-date>
  <activity-date iso-date="2021-06-30" type="3"></activity-date>
  <activity-date iso-date="2021-06-30" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">Communications</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">Murad HIRJI</narrative>
   </person-name>
   <job-title>
    <narrative xml:lang="EN">Senior Digital Architect</narrative>
   </job-title>
   <telephone>+41 58 791 1700</telephone>
   <email>murad.hirji@theglobalfund.org</email>
   <website>https://www.theglobalfund.org</website>
   <mailing-address>
    <narrative xml:lang="EN">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="4">
   <organisation>
    <narrative xml:lang="EN">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">Communications</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">Murad HIRJI</narrative>
   </person-name>
   <job-title>
    <narrative xml:lang="EN">Senior Digital Architect</narrative>
   </job-title>
   <telephone>+41 58 791 1700</telephone>
   <email>murad.hirji@theglobalfund.org</email>
   <website>https://www.theglobalfund.org</website>
   <mailing-address>
    <narrative xml:lang="EN">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <organisation>
    <narrative xml:lang="EN">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">Grant Management Division</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">Alexey BOBRIK</narrative>
   </person-name>
   <job-title>
    <narrative xml:lang="EN">Fund Portfolio Manager</narrative>
   </job-title>
   <telephone>+41 58 791 1700</telephone>
   <email>alexey.bobrik@theglobalfund.org</email>
   <website>https://www.theglobalfund.org</website>
   <mailing-address>
    <narrative xml:lang="EN">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="3">
   <organisation>
    <narrative xml:lang="EN">The Global Fund to Fight AIDS Tuberculosis and Malaria</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">Grant Management Division</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">Alexey BOBRIK</narrative>
   </person-name>
   <job-title>
    <narrative xml:lang="EN">Fund Portfolio Manager</narrative>
   </job-title>
   <telephone>+41 58 791 1700</telephone>
   <email>alexey.bobrik@theglobalfund.org</email>
   <website>https://www.theglobalfund.org</website>
   <mailing-address>
    <narrative xml:lang="EN">The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
   </mailing-address>
  </contact-info>
  <activity-scope code="4"></activity-scope>
  <recipient-country code="UZ" percentage="100">
   <narrative xml:lang="EN">Uzbekistan</narrative>
  </recipient-country>
  <sector code="12263" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Tuberculosis</narrative>
  </sector>
  <country-budget-items vocabulary="4">
   <budget-item code="0E92B28E-6628-4A93-91F4-24A0E3F68B43" percentage="0.98" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Communication Material and Publications (CMP)</narrative>
    </description>
   </budget-item>
   <budget-item code="C7B597A0-B5A0-4104-8A99-BA94F1C26180" percentage="8.83" vocabulary="4">
    <description>
     <narrative xml:lang="EN">External Professional services (EPS)</narrative>
    </description>
   </budget-item>
   <budget-item code="1BDFF48D-DF9D-43D5-BCDF-56FECE799046" percentage="4.99" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Health Products - Equipment (HPE)</narrative>
    </description>
   </budget-item>
   <budget-item code="B035C5CE-BA09-412B-B386-BB992AA6A20F" percentage="30" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Health Products - Non-Pharmaceuticals (HPNP)</narrative>
    </description>
   </budget-item>
   <budget-item code="AEEC85E4-0556-495F-8F31-584DD9FF4EF3" percentage="14.14" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Human Resources (HR)</narrative>
    </description>
   </budget-item>
   <budget-item code="400CEE75-C251-4A85-AA43-BD93DF71A408" percentage="1.1" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Indirect and Overhead Costs</narrative>
    </description>
   </budget-item>
   <budget-item code="FDEDB289-7073-424F-8780-856D2FB8F704" percentage="0.9" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Infrastructure (INF)</narrative>
    </description>
   </budget-item>
   <budget-item code="8FF157DA-C279-44D8-8148-6161B33C9E92" percentage="12.71" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Non-health equipment (NHP)</narrative>
    </description>
   </budget-item>
   <budget-item code="DC588E6C-6B65-46A8-90D7-3ACCD004E54D" percentage="15.84" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Procurement and Supply-Chain Management costs (PSM)</narrative>
    </description>
   </budget-item>
   <budget-item code="F4B643AF-C501-4424-B4BD-74AA0DA9F006" percentage="10.52" vocabulary="4">
    <description>
     <narrative xml:lang="EN">Travel related costs (TRC)</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="2" type="2">
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-03-31"></period-end>
   <value currency="USD" value-date="2021-01-01">591439</value>
  </budget>
  <budget status="2" type="2">
   <period-start iso-date="2021-04-01"></period-start>
   <period-end iso-date="2021-06-30"></period-end>
   <value currency="USD" value-date="2021-01-01">249774</value>
  </budget>
  <capital-spend percentage="4.99"></capital-spend>
  <transaction ref="a2142a62-dabf-44fe-a13a-4c810e6bb89d">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-04-08"></transaction-date>
   <value currency="USD" value-date="2021-04-08">643644</value>
   <description>
    <narrative xml:lang="EN">Global Fund Commitment to UZB-T-RSSPMCPhP.</narrative>
   </description>
   <aid-type code="C01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction ref="dd727f4b-c413-41fa-b7bb-94ef6736ec1a">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-06-10"></transaction-date>
   <value currency="USD" value-date="2021-06-10">197536.22</value>
   <description>
    <narrative xml:lang="EN">Global Fund Commitment to UZB-T-RSSPMCPhP.</narrative>
   </description>
   <aid-type code="C01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction ref="91e6c8a1-ef91-4d0b-84ec-42dbb9f387e2">
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-10-14"></transaction-date>
   <value currency="USD" value-date="2021-10-14">-91959.02</value>
   <description>
    <narrative xml:lang="EN">Global Fund Commitment to UZB-T-RSSPMCPhP.</narrative>
   </description>
   <aid-type code="C01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction ref="d1e812f6-f9a4-4a57-8a06-65143cbad801">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-04-16"></transaction-date>
   <value currency="USD" value-date="2021-04-16">558398</value>
   <description>
    <narrative xml:lang="EN">Global Fund disbursement to UZB-T-RSSPMCPhP.</narrative>
   </description>
   <aid-type code="C01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction ref="dee0574a-4adc-44c9-9faa-c32129ebb2b5">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-04-30"></transaction-date>
   <value currency="USD" value-date="2021-04-30">15810.5</value>
   <description>
    <narrative xml:lang="EN">Global Fund disbursement to UZB-T-RSSPMCPhP.</narrative>
   </description>
   <aid-type code="C01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction ref="799e34c0-1ff3-484f-8650-c5453af27dfc">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-06-04"></transaction-date>
   <value currency="USD" value-date="2021-06-04">32973.86</value>
   <description>
    <narrative xml:lang="EN">Global Fund disbursement to UZB-T-RSSPMCPhP.</narrative>
   </description>
   <aid-type code="C01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction ref="1bc5771d-c220-446c-8e31-d44b67dcdcfa">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-07-15"></transaction-date>
   <value currency="USD" value-date="2021-07-15">79865.12</value>
   <description>
    <narrative xml:lang="EN">Global Fund disbursement to UZB-T-RSSPMCPhP.</narrative>
   </description>
   <aid-type code="C01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction ref="54fd752e-c1ab-41c2-b779-7ef8158a551a">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-08-03"></transaction-date>
   <value currency="USD" value-date="2021-08-03">25712.08</value>
   <description>
    <narrative xml:lang="EN">Global Fund disbursement to UZB-T-RSSPMCPhP.</narrative>
   </description>
   <aid-type code="C01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <result aggregation-status="0" type="1">
   <title>
    <narrative xml:lang="EN">Coverage / Output indicator for UZB-T-RSSPMCPhP</narrative>
   </title>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Number of notified cases of all forms of TB (i.e. bacteriologically confirmed + clinically diagnosed), new and relapse cases</narrative>
    </title>
    <baseline year="2019">
     <dimension name="HIV test status" value="Not documented"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 0</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="TB case definition" value="Bacteriologically confirmed"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 11264</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Age" value="15+"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 13832</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="HIV test status" value="Negative"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 15625</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 16272</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Age" value="&lt;15"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 2440</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="HIV test status" value="Positive"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 647</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Gender" value="Female"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 7291</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Gender" value="Male"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 8981</narrative>
     </comment>
    </baseline>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Treatment success rate- all forms: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period, new and relapse cases</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 13267 Denominator: 14705 Percentage: 90.22</narrative>
     </comment>
    </baseline>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Percentage of cases with RR-TB and/or MDR-TB started on treatment for MDR-TB who were lost to follow up during the first six months of treatment</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 15 Denominator: 1084 Percentage: 1.38</narrative>
     </comment>
    </baseline>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Percentage of people living with HIV initiated on ART who are screened for TB in HIV treatment settings</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 29910 Denominator: 42425 Percentage: 70.50</narrative>
     </comment>
    </baseline>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Number of cases with RR-TB and/or MDR-TB that began second-line treatment</narrative>
    </title>
    <baseline year="2019">
     <dimension name="Gender" value="Male"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 1432</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Age" value="15+"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 2189</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 2216</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="TB regimen" value="Short regimens"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 307</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="TB regimen" value="New TB drugs"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 426</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Age" value="&lt;15"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 78</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Gender" value="Female"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 835</narrative>
     </comment>
    </baseline>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 481 Denominator: 647 Percentage: 74.00</narrative>
     </comment>
    </baseline>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Number of TB cases with RR-TB and/or MDR-TB notified</narrative>
    </title>
    <baseline year="2019">
     <dimension name="Gender" value="Female"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 1044</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Gender" value="Male"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 1803</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 2662</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Age" value="15+"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 2788</narrative>
     </comment>
    </baseline>
    <baseline year="2019">
     <dimension name="Age" value="&lt;15"></dimension>
     <comment>
      <narrative xml:lang="EN">Numerator: 59</narrative>
     </comment>
    </baseline>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Number of cases of XDR TB enrolled on treatment</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 602</narrative>
     </comment>
    </baseline>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Percentage of TB patients with DST result for at least Rifampicin among the total number of notified (new and retreatment) cases in the same year</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Numerator: 8295 Denominator: 8328 Percentage: 99.60</narrative>
     </comment>
    </baseline>
   </indicator>
  </result>
  <result aggregation-status="0" type="2">
   <title>
    <narrative xml:lang="EN">Outcome indicator for UZB-T-RSSPMCPhP</narrative>
   </title>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Treatment success rate of RR TB and/or MDR-TB: Percentage of cases with RR and/or MDR-TB successfully treated</narrative>
    </title>
    <baseline year="2019">
     <dimension name="TB case definition" value="XDR TB"></dimension>
     <comment>
      <narrative xml:lang="EN">Text: 59</narrative>
     </comment>
    </baseline>
    <baseline year="2018">
     <comment>
      <narrative xml:lang="EN">Text: 61%</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2021-06-30"></period-end>
     <target>
      <comment>
       <narrative xml:lang="EN">Percentage: 75.00</narrative>
       <narrative xml:lang="EN">Target for: 2020</narrative>
      </comment>
     </target>
    </period>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Notification of RR-TB and/or MDR-TB cases &#x2013; Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB as a proportion of all estimated RR-TB and/or MDR-TB cases</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Text: 64.4%</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2021-06-30"></period-end>
     <target>
      <comment>
       <narrative xml:lang="EN">Percentage: 80.00</narrative>
       <narrative xml:lang="EN">Target for: 2020</narrative>
      </comment>
     </target>
    </period>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">TB treatment coverage: Percentage of new and relapse cases that were notified and treated among the estimated number of incident TB cases in the same year (all form of TB - bacteriologically confirmed plus clinically diagnosed)</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Text: 73%</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2021-06-30"></period-end>
     <target>
      <comment>
       <narrative xml:lang="EN">Percentage: 82.00</narrative>
       <narrative xml:lang="EN">Target for: 2020</narrative>
      </comment>
     </target>
    </period>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">Treatment success rate of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapse cases</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Text: 92%</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2021-06-30"></period-end>
     <target>
      <comment>
       <narrative xml:lang="EN">Percentage: 90.50</narrative>
       <narrative xml:lang="EN">Target for: 2020</narrative>
      </comment>
     </target>
    </period>
   </indicator>
  </result>
  <result aggregation-status="0" type="3">
   <title>
    <narrative xml:lang="EN">Impact indicator for UZB-T-RSSPMCPhP</narrative>
   </title>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">TB mortality rate per 100,000 population</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Text: 1.2</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2021-06-30"></period-end>
     <target>
      <comment>
       <narrative xml:lang="EN">Numerator: 1.2</narrative>
       <narrative xml:lang="EN">Target for: 2020</narrative>
      </comment>
     </target>
    </period>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">RR-TB and/or MDR-TB prevalence among new TB patients: Proportion of new TB cases with RR-TB and/or MDR-TB</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Text: 12</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2021-06-30"></period-end>
     <target>
      <comment>
       <narrative xml:lang="EN">Percentage: 12.00</narrative>
       <narrative xml:lang="EN">Target for: 2020</narrative>
      </comment>
     </target>
    </period>
   </indicator>
   <indicator aggregation-status="0" measure="5">
    <title>
     <narrative xml:lang="EN">TB incidence rate per 100,000 population</narrative>
    </title>
    <baseline year="2019">
     <comment>
      <narrative xml:lang="EN">Text: 67</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2021-01-01"></period-start>
     <period-end iso-date="2021-06-30"></period-end>
     <target>
      <comment>
       <narrative xml:lang="EN">Numerator: 59.25</narrative>
       <narrative xml:lang="EN">Target for: 2020</narrative>
      </comment>
     </target>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
